- The retinoblastoma protein (pRb) is one of the most important tumour‑suppressor proteins in the eukaryotic cell cycle. Encoded by the RB1 gene, pRb acts as a molecular gatekeeper that prevents cells from entering S phase until they are fully prepared. Its central function is to restrain transcription factors that drive DNA replication, thereby ensuring that cell‑cycle progression occurs only under appropriate physiological conditions. Because of its pivotal role in controlling proliferation, pRb is frequently disrupted in human cancers, making it a major focus of research in cell‑cycle regulation and tumour suppression.
- During early G1, pRb exists in a hypophosphorylated state that allows it to bind and inhibit E2F transcription factors. E2Fs activate genes required for DNA synthesis, including Cyclin E, Cyclin A, replication enzymes and components of the MCM complex. By binding E2F, pRb prevents premature expression of these S‑phase genes, effectively blocking cell‑cycle progression. As cells receive mitogenic signals, Cyclin D–CDK4/6 complexes begin phosphorylating pRb. This phosphorylation gradually weakens pRb’s interaction with E2F. Once pRb becomes hyperphosphorylated, it releases E2F completely, allowing transcription of S‑phase genes and committing the cell to DNA replication. This irreversible decision point is known as the restriction point, and pRb is its central regulator.
- Beyond its role in E2F inhibition, pRb also influences chromatin structure. It recruits histone deacetylases, SWI/SNF chromatin‑remodelling complexes and histone methyltransferases to E2F‑responsive promoters. These interactions create a repressive chromatin environment that stabilises the G1 state. In this way, pRb acts not only as a transcriptional inhibitor but also as a chromatin architect that reinforces cell‑cycle arrest.
- pRb plays an essential role in maintaining cellular quiescence and supporting terminal differentiation. In neurons, muscle cells and other post‑mitotic tissues, pRb helps silence cell‑cycle genes permanently, ensuring that differentiated cells do not re‑enter the cell cycle. Its sustained activity preserves tissue integrity and prevents inappropriate proliferation in specialised cells.
- Loss or inactivation of pRb is one of the most common events in human cancers. Tumour cells disable pRb through RB1 mutations, hyperactive CDK4/6 signalling, epigenetic silencing or viral oncoproteins such as HPV E7. Without functional pRb, E2F becomes constitutively active, driving uncontrolled S‑phase entry, replication stress and genomic instability. Cancers lacking pRb often show high proliferation rates and resistance to cell‑cycle checkpoints. This is why CDK4/6 inhibitors are effective in tumours with intact pRb—they prevent pRb hyperphosphorylation, restoring its ability to restrain E2F.
- pRb also works closely with p53, another major tumour suppressor. While pRb prevents inappropriate S‑phase entry, p53 responds to DNA damage by inducing cell‑cycle arrest or apoptosis. Together, they form a dual‑layer defence system in which pRb blocks entry into S phase and p53 eliminates cells with damaged DNA. Loss of both pathways is strongly associated with aggressive tumour phenotypes.
- In summary, pRb is a master regulator of the G1–S transition, acting through E2F inhibition, chromatin remodelling and integration of mitogenic signals. Its role extends beyond proliferation control to differentiation, quiescence and genome protection. When pRb is lost or inactivated, cells bypass critical checkpoints, leading to uncontrolled growth and cancer development. Understanding pRb provides deep insight into cell‑cycle regulation and tumour suppression.
